ABSTRACT
OBJECTIVES: Lung resection surgery with one-lung ventilation leads to an inflammatory response. Surgical manipulation can play a key role in this response. Sevoflurane, a commonly used volatile anaesthetic, has a proven anti-inflammatory effect. Our main goal was to evaluate the segregated effect of surgical manipulation during lung resection surgery and the protective role of sevoflurane with regard to this response. METHODS: Fifteen pigs underwent left thoracotomy for caudal lobectomy under general anaesthesia. The animals were divided into 3 groups: control, sevoflurane and sham. The animals in the sham group underwent left thoracotomy and one-lung ventilation over 120 min, without lobectomy. The animals in the sevoflurane group received anaesthetic maintenance with sevoflurane. The animals in the sham group and the control group received propofol during the procedure. Lung biopsies were collected before the procedure (left caudal lobe) and 24 h later (right mediastinal lobe and left upper lobe). The samples were stored to measure levels of inflammatory markers (IL-1, TNF-α and ICAM-1), apoptotic mediators (BAD, BAX, BCL-2 and Caspase-3), Syndecan-1, MicroRNAs 182, 145 and lung oedema. RESULTS: Surgical manipulation increased the expression of inflammation (IL-1, TNF-α and ICAM-1) and proapoptotic mediators (BAX, BAD and Caspase-3). It also caused degradation of endothelial glycocalyx (Syndecan-1) and pulmonary oedema. Administration of sevoflurane reduced the elevation of inflammatory markers, degradation of glycocalyx and pulmonary oedema observed in the control group. CONCLUSIONS: Surgical manipulation of the collapsed lung could increase the expression of inflammation and proapoptotic mediators and cause tissue damage in the form of pulmonary oedema. Sevoflurane could attenuate this molecular response and pulmonary oedema.
Subject(s)
Inflammation , Lung Diseases , Lung , One-Lung Ventilation , Pneumonectomy , Sevoflurane , Animals , Anesthetics, Inhalation/administration & dosage , Biomarkers/metabolism , Cytokines/metabolism , Disease Models, Animal , Inflammation/etiology , Inflammation/metabolism , Inflammation/prevention & control , Lung/surgery , Lung Diseases/metabolism , Lung Diseases/surgery , One-Lung Ventilation/methods , Pneumonectomy/adverse effects , Random Allocation , Sevoflurane/administration & dosage , Swine , Swine, MiniatureABSTRACT
Introducción: En la literatura científica se han publicado resultados contradictorios sobre el valor pronóstico de la pérdida de la expresión del antígeno de grupo sanguíneo A (GSA) en el cáncer de pulmón, por lo que analizamos retrospectivamente este hecho en nuestra serie quirúrgica. Pacientes y métodos. En un estudio multicéntrico de 402 pacientes con carcinoma no microcítico de pulmón (CNMP) en estadio I patológico según la nueva clasificación TNM-2009 se analizó la influencia pronóstica de la pérdida de la expresión del antígeno del GSA en los 209 pacientes con grupos sanguíneos A o AB. Resultados: La supervivencia a los 5 años de los pacientes en estadio I patológico que mantenían la expresión del antígeno del GSA fue del 73%, frente a una supervivencia del 53% en los pacientes que habían perdido la expresión del mismo (p=0,03). Cuando se analizó la supervivencia subdividiendo la muestra en estadios IA y IB, solo se alcanzó la significación estadística en el estadio IA (p=0,038). Al analizar la supervivencia según el tipo histológico, los pacientes con adenocarcinoma que perdían la expresión del antígeno del GSA tenían una menor supervivencia, con una p estadísticamente muy significativa (p=0,003). El análisis multivariable mostró que la edad, el género y la expresión del antígeno del GSA eran factores pronósticos independientes. Conclusiones: La pérdida de la expresión del antígeno del grupo sanguíneo A tiene una influencia pronóstica negativa en el CNMP estadio I patológico, sobre todo en el tipo histológico adenocarcinoma(AU)
Introduction: In the scientific literature, contradictory results has been published on the prognostic value of the loss of expression of blood group antigen A (BAA) in lung cancer. The objective of our study was to analyze this fact in our surgical series. Patients and methods: In a multicenter study, 402 non-small-cell lung cancer (NSCLC) patients were included. All were classified as stage-I according to the last 2009-TNM classification. We analyzed the prognostic influence of the loss of expression of BAA in the 209 patients expressing blood group A or AB. Results: The 5-year cumulative survival was 73% for patients expressing BAA vs 53% for patients with loss of expression (P=.03). When patients were grouped into stages IA and IB, statistical significance was only observed in stage I-A (P=.038). When we analyzed the survival according to histologic type, those patients with adenocarcinoma and loss of expression of BAA had a lower survival rate that was statistically very significant (P=.003). The multivariate analysis showed that age, gender and expression of BAA were independent prognostic factors. Conclusions: The loss of expression of blood group antigen A has a negative prognostic impact in stage I NSCLC, especially in patients with adenocarcinoma(AU)
Subject(s)
Humans , Male , Female , Prognosis , Carcinoma/complications , Carcinoma/diagnosis , Carcinoma, Non-Small-Cell Lung/complications , Carcinoma, Non-Small-Cell Lung/diagnosis , Lung Neoplasms/complications , Lung Neoplasms/diagnosis , Immunohistochemistry/methods , Immunohistochemistry/standards , Immunohistochemistry , /methods , Adenocarcinoma/complicationsABSTRACT
INTRODUCTION: In the scientific literature, contradictory results has been published on the prognostic value of the loss of expression of blood group antigen A (BAA) in lung cancer. The objective of our study was to analyze this fact in our surgical series. PATIENTS AND METHODS: In a multicenter study, 402 non-small-cell lung cancer (NSCLC) patients were included. All were classified as stage-I according to the last 2009-TNM classification. We analyzed the prognostic influence of the loss of expression of BAA in the 209 patients expressing blood group A or AB. RESULTS: The 5-year cumulative survival was 73% for patients expressing BAA vs 53% for patients with loss of expression (P=.03). When patients were grouped into stages IA and IB, statistical significance was only observed in stage I-A (P=.038). When we analyzed the survival according to histologic type, those patients with adenocarcinoma and loss of expression of BAA had a lower survival rate that was statistically very significant (P=.003). The multivariate analysis showed that age, gender and expression of BAA were independent prognostic factors. CONCLUSIONS: The loss of expression of blood group antigen A has a negative prognostic impact in stage I NSCLC, especially in patients with adenocarcinoma.
Subject(s)
ABO Blood-Group System/metabolism , Antigens, Neoplasm/metabolism , Carcinoma, Non-Small-Cell Lung/enzymology , Chromosome Deletion , Chromosomes, Human, Pair 9/genetics , DNA Methylation , Gene Deletion , Lung Neoplasms/enzymology , N-Acetylgalactosaminyltransferases/deficiency , Neoplasm Proteins/deficiency , Adenocarcinoma/chemistry , Adenocarcinoma/enzymology , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/chemistry , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Female , Humans , Immunoenzyme Techniques , Lung Neoplasms/chemistry , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Middle Aged , N-Acetylgalactosaminyltransferases/genetics , N-Acetylgalactosaminyltransferases/metabolism , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Neoplasm Staging , Pneumonectomy , Prognosis , Retrospective StudiesABSTRACT
Introducción: La nueva clasificación TNM de 2009 ha introducido importantes modificaciones en la estadificacióndel cáncer de pulmón. El objetivo de este trabajo es validar nuestra serie de pacientes concarcinoma no microcítico de pulmón en estadio I patológico según la séptima edición de la clasificaciónTNM de los tumores malignos y analizar los factores relacionados con el pronóstico.Pacientes y métodos: Se realizó un estudio retrospectivo y multicéntrico. Para el análisis de supervivenciase utilizó el método de Kaplan-Meier y para el análisis multivariable, la regresión de Cox. Se analizaronlas siguientes variables: edad, sexo, estadio patológico, categoría T, tipo histológico, tipo de resección ytamaño tumoral.Resultados: Se incluyó a 402 pacientes con un seguimiento medio de 70,18 meses. La supervivencia globala los 5 años fue del 68%. Los varones y los pacientes mayores de 70 años tenían una menor supervivencia.El pronóstico empeoraba a medida que aumentaba el estadio patológico, la categoría T y el tamañotumoral. No encontramos diferencias pronósticas estadísticamente significativas en relación con el tipohistológico y el tipo de resección practicada. El análisis multivariable mostró que la edad, el sexo y elestadio patológico son factores pronósticos independientes.Conclusiones: Los resultados de supervivencia y el análisis de factores pronósticos de nuestra serie seajustan a los publicados en la nueva clasificación TNM de 2009. El factor pronóstico más importante esel estadio patológico. Otros factores pronósticos desfavorables son el sexo masculino y la edad mayor de70 años (AU)
Introduction: The new 2009 TNM classification introduced important modifications in lung cancer staging. The aim of this study is to validate our series of patients with pathologic stage I non-small-cell lung canceraccording to the 7th edition of the TNM classification of malignant tumors and to the factors related withprognosis.Patients and methods: A multicenter retrospective study was performed. Survival rates were calculated by the Kaplan-Meier method, and for multivariate analyses, Cox proportional hazards regression model was used. The following variables were analyzed: age, sex, pathologic stage, T category, histology, type of resection and tumor size. Results: A total of 402 patients were included. Mean follow-up was 70.18 months. Overall 5-year survivalwas 68%. Males and patients over 70 had lower survival. Prognosis worsened with increasing pathologicstage, T category and tumor size. We found no statistically significant differences in prognosis for histologyor type of resection. Multivariate analysis showed age, sex and pathologic stage to be independentprognostic factors.Conclusions: Survival results and the analysis of prognostic factors in our series are similar to those publishedin the new 2009 TNM classification. The most important prognostic factor is pathologic stage. Otheradverse prognostic factors include male sex and age over 70 (AU)
Subject(s)
Humans , Male , Female , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Survival Analysis , Prognosis , Carcinoma, Non-Small-Cell Lung/surgery , Carcinoma, Non-Small-Cell Lung/epidemiologyABSTRACT
INTRODUCTION: The new 2009 TNM classification introduced important modifications in lung cancer staging. The aim of this study is to validate our series of patients with pathologic stage I non-small-cell lung cancer according to the 7th edition of the TNM classification of malignant tumors and to the factors related with prognosis. PATIENTS AND METHODS: A multicenter retrospective study was performed. Survival rates were calculated by the Kaplan-Meier method, and for multivariate analyses, Cox proportional hazards regression model was used. The following variables were analyzed: age, sex, pathologic stage, T category, histology, type of resection and tumor size. RESULTS: A total of 402 patients were included. Mean follow-up was 70.18 months. Overall 5-year survival was 68%. Males and patients over 70 had lower survival. Prognosis worsened with increasing pathologic stage, T category and tumor size. We found no statistically significant differences in prognosis for histology or type of resection. Multivariate analysis showed age, sex and pathologic stage to be independent prognostic factors. CONCLUSIONS: Survival results and the analysis of prognostic factors in our series are similar to those published in the new 2009 TNM classification. The most important prognostic factor is pathologic stage. Other adverse prognostic factors include male sex and age over 70.
